title: Antibodies against human herpesvirus 8 in subjects with non-venereal dermatological conditions.
abstract: BACKGROUND
  Human herpesvirus 8 (HHV8) is considered as the infectious cofactor involved in the pathogenesis of Kaposi's sarcoma (KS). Its seroprevalence and modes of transmission in the general population are still undetermined.
  
  
  OBJECTIVE
  We aimed to estimate the prevalence of HHV8 infection in a population at low risk for sexually transmitted diseases.
  
  
  METHODS
  We conducted a seroepidemiological survey on randomly selected individuals attending the dermatology department of a teaching hospital in Rome. Of 257 patients, 248 had their blood analysed for anti-HHV8 antibodies and 201 completed a standardized interview. Serological analysis was performed by an immunofluorescence assay able to detect antilytic antibodies.
  
  
  RESULTS
  We found an overall seroprevalence of 15.7% (95% confidence interval, CI 11.4-20.9%), similar in men and women (15.1% vs. 16.3%) and higher at older ages. Seropositivity was not related to sexual habits, while it was significantly associated with a history of hepatitis (seroprevalence 34.6%, adjusted odds ratio, OR 4.08, 95% CI 1.52-11.00) and with a diagnosis of non-melanoma skin cancer (42.9%, OR 4.20, 95% CI 1.26-14.02) or atypical naevi (35.3%, OR 6.21, 95% CI 1.85-20.86).
  
  
  CONCLUSIONS
  Our data suggest that a non-sexual mode of transmission of HHV8 infection is plausible in an Italian population at low risk for sexually transmitted diseases and that other factors, besides differences in prevalence of HHV8 infection, may be involved in the epidemiology of classical KS. The unexpectedly high seropositivity rates in subjects with non-melanoma skin cancer and atypical naevi should be viewed with caution and require confirmation.
authors.affiliation: Clinical Epidemiology Unit, Istituto Dermopatico dell'Immacolata, IRCCS, Via dei Monti di Creta 104, 00167 Rome, Italy, d.abeni@idi.it
authors.forename: C
authors.initials: C
authors.lastname: Masini
authors.forename: D D
authors.initials: DD
authors.lastname: Abeni
authors.forename: M S
authors.initials: MS
authors.lastname: Cattaruzza
authors.forename: M
authors.initials: M
authors.lastname: Capuano
authors.forename: C
authors.initials: C
authors.lastname: Pedicelli
authors.forename: F
authors.initials: F
authors.lastname: Cerimele
authors.forename: P
authors.initials: P
authors.lastname: Pasquini
authors.forename: D
authors.initials: D
authors.lastname: Cerimele
authors.forename: G
authors.initials: G
authors.lastname: Fadda
authors.forename: P
authors.initials: P
authors.lastname: Cattani
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D000914:Antibodies, Viral / Q000097:blood*; D005260:Female; D005455:Fluorescent Antibody Technique; D006505:Hepatitis / Q000150:complications; D006566:Herpesviridae Infections / Q000097:blood / Q000276:immunology* / Q000635:transmission; D019288:Herpesvirus 8, Human / Q000276:immunology*; D006801:Humans; D007558:Italy; D008297:Male; D008875:Middle Aged; D009506:Nevus / Q000150:complications; D016017:Odds Ratio; D012307:Risk Factors; D016036:Seroepidemiologic Studies; D012725:Sexual Behavior; D012749:Sexually Transmitted Diseases / Q000150:complications / Q000276:immunology*; D012878:Skin Neoplasms / Q000150:complications
chemical_list: D000914:Antibodies, Viral